Natco Pharma Limited is pleased to announce that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received approval for its Abbreviated New Drug Application (ANDA) for Carfilzomib Vials ANDA (generic for KYPROLIS), from the U.S. Food and Drug Administration (USFDA).
- Read more about NATCO receives approval for Carfilzomib Vials ANDA in the US market
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/natco-receives-approval-for-carfilzomib-vials-anda-in-the-us-market
No comments:
Post a Comment